<DOC>
	<DOCNO>NCT00802594</DOCNO>
	<brief_summary>Human African Trypanosomiasis sleeping sickness make spectacular return last decade , many place demand largely surpasses capacity treatment center . Treatment disease remain unsatisfactory . All currently use drug must administer parenterally , treatment lengthy , adverse drug reaction frequent . There currently drug might use tool support disease control easily administer low toxicity . This study aim assess efficacy DB289 , new , oral drug treatment first stage sleep sickness . The project execute framework international consortium consist dozen partner academia , industry , Ministries Health Angola Democratic Republic Congo .</brief_summary>
	<brief_title>A Trial DB289 Treatment Stage I African Trypanosomiasis</brief_title>
	<detailed_description>This single-center , open label , non-controlled Phase IIa trial . Patients first stage T.b . gambiense sleep sickness receive 100 mg DB289 orally twice day 5 day . Subjects meet entry criterion enrol single site . A total 30 patient enrolled trial . Enrollment plan begin third quarter 2001 complete 2-3 month . The study conduct Trypanosomiasis Reference Center , Viana ( ICCT ) , Angola , Trypanosomiasis Treatment Center Maluku , Congo .</detailed_description>
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<criteria>1 . The patient early stage T. b. gambiense infection i.e . parasitologically confirmed infection blood lymph less equal 5 WBC mm3 detect CSF microscopic examination 2 . Patient 16 year old 3 . Patient minimal weight 45 kilogram 4 . If patient female child bear potential ( woman consider nonchild bear potential post menopausal 2 year hysterectomy ) , lactate , negative urine pregnancy test result within 24 hour prior DB289 treatment agree use medically proven method contraception ( abstinence sexual intercourse acceptable ) day consent 7 Days DB289 treatment completion ( Study Day 12 ) . 5 . Patient sign Informed Consent . If patient minor , legal guardian sign Informed Consent 1 . The patient late stage T.b . gambiense infection i.e . presence parasite CSF upon microscopic examination , positive ( titer great 1/4 ) latex / IgM test , positive latex / T.b.g . 2 . Active clinically relevant medical condition Investigator opinion may jeopardize subject safety interfere participation study , include limited : significant liver disease , chronic pulmonary disease , significant cardiovascular disease significant ECG anomaly elongate QTc ( correct ) interval 430 msec men 450 msec woman , diabetes , thyroid disease , gout , infection include know HIV infection , CNS trauma seizure disorder . 3 . Clinically significant abnormal laboratory value screen include : Prothrombin Time &gt; 1.25 time upper limit normal ( ULN ) Liver enzyme AST ALT &gt; 2 time ULN Total bilirubin &gt; 1.5 time ULN Serum Creatinine &gt; 1.5 time ULN 4 . Traumatic lumbar puncture ( i.e . red blood cell visible CSF ) 5 . Coma Score less 9 Glasgow Coma Scale ( Appendix 8 ) 6 . Withdrawal consent time study 7 . Any condition compromise ability communicate investigator require completion study . 8 . The subject previously treat African Trypanosomiasis . 9 . The subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>first stage</keyword>
	<keyword>T.b . gambiense</keyword>
	<keyword>sleep sickness</keyword>
	<keyword>Patients first stage T.b . gambiense sleep sickness</keyword>
</DOC>